Parmax Pharma Ltd
Incorporated in 1994, Parmax Pharma Ltd manufactures bulk drugs, drugs intermediates, and specialty chemicals[1]
- Market Cap ₹ 14.2 Cr.
- Current Price ₹ 38.0
- High / Low ₹ 55.0 / 28.7
- Stock P/E
- Book Value ₹ -5.32
- Dividend Yield 0.00 %
- ROCE -12.5 %
- ROE %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 30.5 to 16.6 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 30.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 28.20 | |
0.02 | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 27.94 | |
Operating Profit | -0.02 | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | -3.37 | 0.26 |
OPM % | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.62% | -30.58% | 0.92% | ||||
0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.10 | 0.09 | 0.06 | 0.04 | 0.05 | -1.03 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.59 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.03 |
Profit before tax | 0.04 | 0.04 | 0.01 | 0.01 | 0.00 | 0.10 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -2.39 |
Tax % | 0.00% | 25.00% | 200.00% | 100.00% | 20.00% | 41.10% | 38.02% | 54.84% | 375.00% | 2.12% | -12.55% | |
0.04 | 0.02 | 0.00 | -0.01 | 0.00 | 0.08 | 0.43 | 0.75 | 0.14 | -0.10 | -5.78 | -2.09 | |
EPS in Rs | 0.10 | 0.05 | 0.00 | -0.03 | 0.00 | 0.21 | 1.15 | 2.00 | 0.37 | -0.27 | -15.45 | -5.59 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 6% |
3 Years: | 16% |
TTM: | 156% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 82% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 4% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.90 | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
Reserves | 0.09 | 0.12 | 0.11 | 0.10 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.40 | -4.38 | -6.44 |
0.92 | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 7.70 | |
0.09 | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.35 | 13.04 | |
Total Liabilities | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 |
2.53 | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.50 | 9.27 | 7.97 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.40 |
2.47 | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 10.38 | |
Total Assets | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.06 | 0.00 | -0.50 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.19 | -0.66 | |
0.00 | 0.00 | 0.00 | -0.19 | -4.23 | -3.41 | -2.40 | -3.15 | -1.53 | -0.94 | -1.59 | -0.70 | |
0.01 | 0.00 | 0.10 | 0.56 | 1.14 | 3.10 | -0.23 | 0.40 | -0.91 | -0.04 | 1.43 | 1.40 | |
Net Cash Flow | 0.00 | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.20 | 0.78 | -1.69 | -0.65 | -0.35 | 0.04 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.70 | 60.28 | 16.57 | ||||
Inventory Days | 203.34 | 278.66 | 88.17 | 107.27 | 154.80 | 286.55 | 123.74 | 56.09 | ||||
Days Payable | 609.39 | 645.07 | 311.84 | 269.40 | 299.82 | 309.82 | 382.60 | 173.18 | ||||
Cash Conversion Cycle | -345.57 | -331.40 | -166.09 | -139.12 | -131.41 | -8.57 | -198.58 | -100.52 | ||||
Working Capital Days | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -115.59 | -40.51 | ||||
ROCE % | 0.82% | 0.81% | 0.20% | 0.19% | 0.66% | 1.56% | 8.40% | 14.34% | 6.13% | 3.67% | -58.49% | -12.49% |
Documents
Announcements
-
Integrated Filing (Financials)
30 May - Audited FY25 results show net loss; fire caused asset loss; audit report qualified due to insurance and investment issues.
- FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31/03/2025. 30 May
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 30TH MAY, 2025
30 May - Parmax Pharma reports FY25 audited loss; fire caused Rs 3.69 Cr asset damage; insurance claim pending; regulatory investment issue noted.
-
Board Meeting Intimation for Meeting Of The Board Will Be Held On Friday, 30Th May, 2025 At 4.00 PM Inter Alia To Consider, Approve The Audited Financial Results Of The Quarter And Financial Year Ended On 31St March, 2025
21 May - Board meeting on 30 May 2025 to approve audited results; trading window closed till 48 hours post announcement.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Parmax Pharma confirms it is not classified as Large Corporate per SEBI circular.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
Business Overview:[1]
Company used to do manufacturing bulk drugs and specialty chemicals but it discontinued its business activities for a few years. It deals in active pharmaceutical ingredients and Contract Manufacturing Operations. It plans to extend its activity to the formulation of Tablets, Ointments,
Capsules, and Injectables.